Antidepressant therapy for unexplained symptoms and symptom syndromes

Journal of Family Practice

Volumn 48, Issue 12, 1999, Pages 980-990

  O'Malley, Patrick G ^a   Jackson, Jeffrey L ^b   Santoro, James ^c   Tomkins, Glen ^a   Balden, Erin ^a   Kroenke, Kurt ^d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c WILLIAM BEAUMONT ARMY MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

Antidepressive agents; Depression; Symptoms and general pathology (non MeSH)

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN RECEPTOR AFFECTING AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; EVIDENCE BASED MEDICINE; FEMALE; FIBROMYALGIA; HEADACHE; HUMAN; IRRITABLE COLON; MALE; PAIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD; SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHRONIC DISEASE; COLONIC DISEASES, FUNCTIONAL; DEPRESSION; EVIDENCE-BASED MEDICINE; FEMALE; FIBROMYALGIA; HEADACHE; HUMANS; MALE; PAIN; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGENTS; SYNDROME;

EID: 0033255497     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Cannon RO, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1995; 332:1529-34.
2. O'Malley PG, Wong PW, Kroenke K, Roy M, Wong. The value of screening for psychiatric disorders prior to upper endoscopy. J Psychosom Res 1998; 44:279-87.
3. O'Malley PG, Jackson JL, Kroenke K, Yoon IK, Hornstein E, Dennis G. The value of screening for psychiatric disorders in rheumatology referrals. Arch Intern Med 1998; 158:2357-62.
4. Katon W, Kleinman A, Rosen G. Depression and somatization: a review. Am J Med 1982; 72:127-35, 241-7.
5. Kroenke K, Spitzer RL, Williams JBW, et al. Physical symptoms in primary care: predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994; 3:774-9.
6. Smith GR. The epidemiology and treatment of depression when it coexists with somatoform disorders, somatization, or pain. Gen Hosp Psychiatry 1992; 14:265-72.
7. Onghena Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992; 49:205-19.
8. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68:217-27.
9. Jung AC, Staiger T, Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med 1997; 12:384-9.
10. The Cochrane Collaboration. The Cochrane library. Oxford, United Kingdom: Update Software; 1996.
11. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996; 17:1-12.
12. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-101.
14. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:209-16.
15. Rosenthal R. The "file drawer problem" and tolerance for null results. Psychol Bull 1979; 86:638-41.
16. Ryan RE. Double blind crossover comparison of BC-105, methylsergide and placebo in the prophylaxis of migraine headache. Headache 1968; 8:118-26.
17. Sjaastad O, Stensrud P. Acta Neurol Scandinav 1969; 45:594-600.
18. Arthur GP, Hornabrook RW. The treatment of migraine with BC-105 (pizotifen): a double-blind trial. N Z Med J 1971; 73:5-9.
19. Hughes RC, Foster JB. BC-105 in the prophylaxis of migraine. Curr Ther Res 1971; 13:63-8.
20. Ryan RE. BC105 a new preparation for the interval treatment of migraine - a double blind evaluation compared with placebo. Headache 1971; 11:6-12.
21. Carroll JD, Maclay WP. Pizotifen (BC-105) in migraine prophylaxis. Curr Med Res Opin 1975; 3:68-71.
22. Heathfield KWG, Stone P, Crowder D. Pizotifen in the treatment of migraine. Practitioner 1977; 218:428-30.
23. Osterman PO. A comparison between placebo, pizotifen, and divascan in migraine prophylaxis. Acta Neurol Scand 1977; 17:61-3.
24. Lawrence ER, Hossain M, Littlestone W. Sanomigran for migraine prophylaxis: controlled multicenter trial in general practice. Headache 1977; 17:109-12.
25. Bademosi O, Osuntokun BO. Pizotifen in the management of migraine. Practitioner 1976; 220:325-37.
26. Louis P, Spierings EL Comparison of flunarizine and pizotifien in migraine treatment: a double-blind study. Cephalgia 1982; 2:197-203.
27. Vilming S, Standenes B, Hedman C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine: a double-blind investigation. Cephalgia 1985; 5:17-23.
28. Behan PO, Connelly K. Prophylaxis of migraine: a comparison between naproxen sodium and pizotifen. Headache 1986; 25:237-9.
29. Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline, and placebo in migraine prophylaxis. Headache 1990; 30:710-5.
30. Cleland PG, Bames D, Elrington GM, Loizou LA, Rawes GD. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur Neurol 1997; 38:31-8.
31. Cerbo R, Casacchia M, Formisano R, et al. Flunarizine-pizotifen single-dose bouble-blind cross-over trial in migraine prophylaxis. Cephalalgia 1986;5:15-8.
32. Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizotifen: a double-blind study in the prophylaxis of migraine. Headache 1986; 25:83-5.
33. Havanka-Kanniainen H, Hokkanen E, Myllyia VV. Eficacy of nimodipine in comparison with pizotifen in the prophylaxis of migraine. Cephalalgia 1987; 7:7-13.
34. Mastrosimone F, Iaccarino C, de Caterina G. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine. J Med 1992; 23:1-16.
35. Monro P, Swade C, Coppen A. Mianserin in the prophylaxis of migraine: a double-blind study. Acta Psychiatr Scand Suppl 1985; 320:98-103.
36. Martucci N, Manna V, Porto C, Agnoli A. Migraine and the noradrenergic control of vasomotricity: a study with alpha-2 stimulant and alpha-2 blocker drugs. Headache 1985; 5:95-100.
37. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973; 36:684-90.
38. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36:695-9.
39. Mathew N. Prophylaxis of migraine and mixed headache: a randomized controlled trial. Headache 1981; 21:105-9.
40. Bonuso S, Di Stasio E, Steardo L. Timed-release dihydroergotamine in the prophylaxis of mixed headache: a study versus amitriptyline. Cephalalgia 1983; 3:175-8.
41. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskom SH, Mason. Migraine prophylaxis: a comparison of propranolol and amitriptyline. Arch Neurol 1987; 44:486-9.
42. Noone JF. Clomipramine in the prevention of migraine. J Int Med Res 1980; 8:49-52.
43. Langohr HD, Gerber WD, Koletzki E, Mayer K, Schroth G. Clomipramine and metoprolol in migraine prophylaxis: a double-blind crossover study. Headache 1985; 25:107-13.
44. Jacobs H. A trial of opipramol in the treatment of migraine. J Neurol Neurosurg Psychiatry 1972; 35:500-4.
45. Zeeberg I, Orholm M, Nielsen JD, Honore PF, Larsen JJV. Femoxetine in the prophylaxis of migraine: a randomized comparison with placebo. Acta Neurol Scand 1981; 64:452-9.
46. Kangasniemi PJ, Nyrke T, Lang AH, Petersen E. Femoxetine - new 5-HT uptake inhibitor - and propranolol in the prophylactic tratment of migraine. Acta Neurol Scand 1983; 68:262-7.
47. Orholm M, Honore PF, Zeeberg. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxiws of migraine. Acta Nueol Scand 1986; 74:235-9.
48. Adly C, Straumarus J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992; 32:101-4.
49. Saper JR, Silberstein SD, Lake AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994; 34:497-502.
50. Boline PD, Kassak K, Bronfort G, Nelson C, Anderson AV. Spinal manipulation versus amitriptyline for the treatment of chronic tension-type headaches: a randomized clinical trial. J Manipulative Physiol Ther 1995; 18:148-54.
51. Diamond S, Baltes BJ. Chronic tension headache - treated with amitriptyline - a double-blind study. Headache 1971; 11:110-6.
52. Gobel H, Hamouz V, Hansen C, et al. Chronic tension-type headache: amitriptyline reduces clinical headache-duration and experimental pain sensitivity but does not alter pericranial muscle activity readings. Pain 1994; 59:241-9.
53. Holroyd KA, Nash JM, Pingel JD, Cordingley GE, Jerome A. A comparison of pharmacological (amitriptyline) and nonpharmacological (cognitive-behavioral) therapies for chronic tension headaches. J Consult Clin Psychol 1991; 59:387-93.
54. Indaco A, Carrieri PB. Amitriptyline in the treatment of headaches in patients with Parkinson's disease: a double-blind placebo-controlled study. Neurology 1988; 38:1720-2.
55. Lance JW, Curran DA. Treatment of chronic tension headache. Lancet 1964; 1:1236-9.
56. Mitsikostas DD, Gatzonis S, Thomas A, Ilias A. Buspirone versus amitriptyline in the treatment of chronic tension-type headache. Acta Neurol Scand 1997; 96:247-51.
57. Okasha A, Ghaleb HA, Sadek. A double-blind trial for the clinical mangement of pschogenic headache. Brit J Psychiat 1973; 122:181-3.
58. Pfaffenrath V, Diener HC, Isler H, et al. Efficacy and tolerability of amitriptylinoxide in the treatment of chronic tension-type headache: a multi-centre controlled study. Cephalalgia 1994; 14:149-55.
59. Morland TJ, Storli OV, Mogstad TE. Doxepin in the prophylactic treatment of mixed 'vascular' and tension headache. Headache 1979; 19:382-3.
60. Fogelholm R, Murros K. Maprotiline in chronic tension headache: a double-blind crossover study. Headache 1985; 25:273-5.
61. Langemark M, Loldrup D, Bech P, Olesen J. Clomipramine and mianserin in the treatment of chronic tension headache: a double-blind controlled trial. Headache 1990; 30:118-21.
62. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996; 61:285-90.
63. Sjaastad O. So-called "tension headache" - the respone to a 5-HT uptake inhibitor: femoxetine. Cephalalgia 1982; 3:53-60.
64. Langemark M, Olesen J. Sulphide and paroxetine in the treatment of chronic tension-type headache: an explanatory double-blind trial. Headache 1994; 34:20-4.
65. Ansink BJJ, Hartman JW, Smakman JG. Ritanserin is not effective in tension headache. Letter. Headache 1992; 32:314.
66. Carrette S, McCain GA, Bell DA, Fam AG. Evaluation of amitripryline in primary fibrositis: a double-blind placebo-controlled study. Arthritis Rheum 1986; 29:655-9.
67. Carrette S, Bell MJ, Reynolds et al. Comparison of amitriptyline, cyclobenzaprine, and placbo in the treatment of fibromyalgia: a randomized double-blind clinical trial. Arthiritis Rheum 1994; 1:32-40.
68. Carrette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995; 38:1211-7.
69. Ginsberg F, Mancaux A, Joos E, Vanhove P, Famaey JP. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskeletal Pain 1996; 4:37-47.
70. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia Arthritis Rheum 1986; 29:1371-7.
71. Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 1991; 18:447-51.
72. Isomeri R, Mikkelsson M, Latikka P, Kammonen K. Effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia. J Musculoskeletal Pain 1993; 1:253-60.
73. Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain responsiveness in patients with fibrosists after successful treatment with amitriptyline. J Rheumatol 1989; 16:98-103.
74. Bibolotti E, Borghi C, Pasculli E, et al. A double-blind comparison of maprotiline and placebo. Clin Trials J 1986; 23:269-80.
75. Caruso I, Sarzi Puttini PC, Boccassini L, et al. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1987;15:154-9.
76. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998; 37:1279-86.
77. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind, crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthitis Rheum 1996; 39:1852-9.
78. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23:255-9.
79. Cantini F, Bellandi F, Niccoli L, Di Munno O. Fluoxetine associated with cyclobenzaprine in the treatment of primary fibromyalgia. Minerva Med 1994; 85:97-100.
80. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61:445-9.
81. Jacobsen S, Danneskiold-Samsoe B, Bach Andersen R. Oral S-adenosylmethionine in primary fibromyalgia: double-blind clinical evaluation. Scand J Rheumatol 1991; 20:294-302.
82. Tavoni A, Vitali C, Bombardieri S, Pasero G. Evaluation of s-adenosylmethionine in primary fibromyalgia: a double-blind crossover study. Am J Med 1987; 83:107-10.
83. Olin R, Klein R, Berg PA. A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides, and phospholipids. Clin Rheumatol 1998; 17:89-94.
84. Steinhart MJ, Wong PY, Zarr ML. Therapeutic usefulness of amitriptyline in spastic colon syndrome. Int J Psychiatry Med 1981; 11:45-57.
85. Greenbaum DS, Mayle JE, Vanegeren LE, et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987; 32:257-66.
86. Heefner JD, Wilder RM, Wilson ID. Irritable colon and depression. Psychosomatics 1978; 19:540-7.
87. Myren J, Groth H, Larssen SE, Larsen S. The effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1982; 17:871-5.
88. Myren J, Lovland B, Larssen SE, Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984; 19:835-43.
89. Tripathi BM, Misra NP, Gupta AK. Evaluation of tricyclic compound (trimipramine) vis-à-vis placebo in irritable bowel syndrome (a double-blind randomised study). JAPI 1983; 31:201-3.
90. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterology 1998; 93:160-5.
91. Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in irritable bowel syndrome. J Gastroenterol Hepatol 1998; 13:738-41.
92. Vij JG, Jiloha RC, Kumar N, Madhu SV, Malika V, Anand BS. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Indian J Psychiatry 1991; 33:243-6.
93. General practitioner clinical trials: a psychotropic agent in dyspepsia Practitioner 1971; 207:830-4.
94. Loldrup D, Langemarck M, Hansen H, Olesen J, Bech P. Clomipramine and mianserin in chronic idiopathic pain syndrome: a placebo controlled study. Psychopharmacology 1989; 99:1-7.
95. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder a double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996; 31:318-25.
96. Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities: a double-blind, placebo controlled trial. Gastroenterolgy 1987; 92:1027-36.
97. Alcoff J, Jones E, Rust P, Newman R. Controlled trial of imipramine for chronic low back pain. J Fam Pract 1982; 14:841-6.
98. Feinmann C, Harris M, Cawley R. Psychogenic facial pain: presentation and treatment. BMJ 1984; 288:436-8.
99. Bech P, Jorgensen B, Norrelund N, et al. Pains as presentation symptoms of depression in liason psychiatry as evidenced by outcome of clomipramine treatment. Nord Psykiatr Tidsskr 1989; 43:89-94.
100. Pilowsky I, Hallett EC, Bassett DL, Thomas PG, Penhall RK. A controlled study of amitriptyline in the treatment of chronic pain. Pain 1982; 14:169-79.
101. Pilowsky I, Barrow G. A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain. Pain 1990; 40:3-19.
102. Stein D, Peri T, Edelstein E, Elizur A, Floman Y. The efficacy of amitriptyline and acetominophen in the management of acute low back pain. Psychosomatics 1996; 37:63-70.
103. Van Houdenhove B, Verstraeten D, Onghena P, De Cuyper H. Chronnic idiopathic pain, mianserin and 'masked' depression. Psychother Psychosom 1992; 58:46-53.
104. Johansson F, Von Knorring L. A double-blind controlled study of a serotonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients. Pain 1979; 7:69-78.
105. Engel CC, Walker EA, Engel AL, Bullis J, Armstrong A. A randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain. J Psychosom Res 1998; 44:203-7.
106. Mihail RC, Crowley JM, Walden BE, Fishburne J, Reinwall JE, Zajtchuk JT. The tricyclic trimipramine in the treatment of subjective tinnitus. Ann Otol Rhinol Laryngol 1988; 97:120-3.
107. Sullivan M, Katon W, Russo J, Dobie R, Sakai C. A randomized trial of nortriptyline for severe chronic tinnitus. Arch Intern Med 1993; 153:2251-9.
108. Natelson BH, Cheu J, Pareja J, Ellis SP, Policastro T, Findley TW. Randomized, bouble blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacology 1996; 124:226-30.
109. Vercoulen JH, Swanink CM, Zitman FG, et al. Randomized double-blind placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996; 347:858-61.
110. Standal JE. Pizotifen as an antidepressant. Acta Psychiat Scand 1977; 56:276-9.
111. Bersani G, Pozzi F, Marini S, Pasini A, Ciani N. 5-HT2 receptor antagonism in dysthymic disorder a double blind placebo-controlled study with ritanserin. Acta Psychiat Scand 1991; 83:244-88.
112. Bressa GM, S-adenosylmethionine as anti-depressant: meta-analysis of clinical studies. Acta Neurol Scand 1994; 154:7-14.
113. Cohen J. Statistical power analysis for the behavioral sciences. New York, NY: Academic; 1969.
114. Fishbain DA, Cutler RB, Rosomoff HL, Steele Rosomoff R. Do antidepressants have an analgesic effect in psychogenic pain and somatoform disorder? A meta-analysis. Psychosomatic Med 1998; 60:503-9.
115. Light RJ, Pillemer DB. Summing up: the science of reviewing research. Cambridge, Mass: Harvard University Press; 1984